NHS weight loss support – Tirzepatide (Mounjaro)

Posted on:

NHS weight loss support – Tirzepatide (Mounjaro)

You may have seen the recent headlines about NHS access to Tirzepatide (Mounjaro) for weight loss in obesity.

‘’From 23 June, people living with obesity will be able to begin accessing tirzepatide (Mounjaro®) for weight loss purposes in primary care settings. This does not mean prescriptions will be provided immediately. It means primary care settings can begin discussions with patients about whether tirzepatide is the right option to improve their health through weight loss.

In Hampshire and the Isle of Wight around 1,000 people currently qualify for the medication based on national eligibility criteria – we are working to set up services quickly however this it will not be available locally until later this year (Autumn) – so please don’t contact your GP just yet as they’re unable to help currently.  We will update this webpage when we have more information.

Access is prioritised for those with the greatest clinical need, it’s for people living with obesity, in poor health with multiple obesity related conditions; as they would benefit most from the treatment.

Who is eligible?

Full qualifying criteria is a BMI (Body Mass Index) of 40 or greater and four or more of the following diagnosed health conditions:

  • type 2 diabetes
  • Hypertension
  • Cardiovascular disease
  • Obstructive sleep apnoea
  • Dyslipidaemia’’

Further information can be found on the Hampshire and IOW ICB website – Weight Loss Support